Deciphering the specific sugar code of the gastro-intestinal cancer
Project/Area Number |
16K10563
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | University of Tsukuba |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
小田 竜也 筑波大学, 医学医療系, 教授 (20282353)
|
Research Collaborator |
Tateno Hiroaki
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 膵癌マーカー / 糖鎖 / レクチン / 早期診断 / 消化器癌 / 腫瘍マーカー / 組織アレイ / 膵癌 / 癌 / レクチンマイクロアレイ |
Outline of Final Research Achievements |
Lectins are proteins that specifically recognize and bind glycans, helpful indication of glycosylation patterns. We performed histochemical staining by 20 types of lectins for cancer and normal tissues. Method: we used a panel of 20 types of lectins histochemical staining for various cancer and normal tissues. The staining patterns were firstly classified according to the ratio between cancer cells and stromal cells. The staining in cancer cell were compared with that of non cancerous pancreatic ductal epithelial cells. Result: Among 20 lectins, lectin Z showed cancer cell staining higher than normal tissue especially in pancreatic cancer. Pancreatic cancer cell 71% were positive for lectin Z, but normal pancreatic duct cells 4% were positive in patients of pancreatic cancer. Conclusion: Our result indicated that specific affinity of lectin Z would be a potential candidate of novel tumor in pancreatic cancer.
|
Academic Significance and Societal Importance of the Research Achievements |
本研究はレクチン工学の技術を応用し、様々な標識レクチンを用いて直接染色することにより、消化器癌における網羅的な糖鎖変化を解析した研究である。我々の解析により、特に腺癌系で正常部と比較し、優位に癌部において反応性が上昇するレクチンが複数同定された。これらは、今後更に解析が進むと糖鎖プローブとして用いることで、これまで用いられてきた腫瘍マーカーに代わって有用な血清マーカーとなったり、特に膵臓癌などでは予後不良患者の割出にも有効となる可能性がある。また現在開発中である、レクチン薬剤複合体による癌治療の新たなターゲットとなる可能性もあり、今後、創薬や診断薬へ繋がることが期待される研究である。
|
Report
(4 results)
Research Products
(8 results)